quattro chiacchiere su sglt2i e gap nel rischio residuo nel paziente con diabete e mrc
Published 1 year ago • 31 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
3:34
quattro chiacchere sugli sglt2i con il prof. michele senni
-
6:57
how does dapagliflozin work? understanding sglt2 inhibitors.
-
2:27
quattro chiacchiere sul paziente “tipo” presente nei centri di diabetologia insieme al prof. candido
-
1:02:42
case study: the importance of glucose variability in the management of type 2 diabetes
-
2:50
quattro chiacchiere sugli sglt2i con il dott. giuseppe musumeci
-
2:52
quattro chiacchiere sugli sglt2i con il dott. andrea di lenarda
-
1:44
sglt2 inhibitors mechanism of action
-
11:17
diabetes medications - sglt 2 inhibitors
-
6:35
do keto diets work as well as sglt2i drugs?
-
16:24
how sglt2 inhibitors protect the kidney
-
27:44
are there alternative mechanisms to explain sglt2i beneficial cveffects in some patients?
-
1:40
dr. daniela geba-type 2 diabetes.mov
-
7:51
gyrru a diabetes
-
17:19
diabetes mellitus type 2 - diagnosis
-
1:03:16
webinar: how to drive key clinical outcomes for patients with diabetes using nutrition therapy
-
4:07
diabetes & children 4
-
2:12
one year randomized, controlled trial of salicylate (salsalate) in patients with type 2 diabetes
-
5:28
pharmacology: drugs for heart failure, animation
-
5:40
quattro chiacchiere sugli sglt2i con il prof. giuseppe patti
-
11:52
safety evaluation of empagliflozin for patients with type 2 diabetes and chronic kidney disease
-
0:54
ask the expert – how do you choose the right medical treatment for diabetes?